Theriva Biologics (TOVX) Registration Filing summary

Company overview and business model

• Diversified clinical-stage company focused on developing therapeutics for cancer and related diseases, with a primary focus on oncology following a 2022 acquisition.

• Lead product candidate is VCN-01, an oncolytic adenovirus in Phase 2 for pancreatic cancer and Phase 1 for retinoblastoma and other solid tumors.

• Pipeline includes SYN-004 and SYN-020 for gastrointestinal diseases, with ongoing efforts to out-license or partner these assets.

• Recent reverse stock split (1-for-25) was implemented to meet NYSE American listing requirements.

Financial performance and metrics

• Aggregate market value of outstanding common stock held by non-affiliates is approximately $9.8 million as of July 24, 2024.

• Approximately $3.7 million of common stock sold in the prior twelve months under Form S-3.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used primarily for working capital and general corporate purposes.

• Specific uses of proceeds for each offering will be detailed in the applicable prospectus supplement.